David Moadel

David Moadel

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Li-Cycle (LICY) Stock Gains 10% After Receiving Government Loan

News of a potential capital infusion is powering LICY stock higher today, but it could take a while for Li-Cycle to receive the funds.

Count on a Comeback for QuantumScape (QS) Stock

QS stock entered double-digit territory after QuantumScape released its quarterly results, and that's just the start of a much bigger rally.

Why SOFI Stock Is on the Cusp of a Comeback

SOFI stock looks ready to run as a Wall Street expert assesses the potentially positive impact of rising interest rates on SoFi Technologies.

FSR Stock Alert: What to Know About Fisker’s Partnership With ChargePoint

It might be good news that Fisker is teaming up with a charging solutions provider, but FSR stock traders are still in a selling mood today.

Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News

FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease.

Why Is Ocean Biomedical (OCEA) Stock Up 260% Today?

OCEA stock is skyrocketing today as Ocean Biomedical highlights a promising proposed treatment for the spread of cancer cells.

Can Walgreens (WBA) Stock Soar 20% From Here? Why This Analyst Thinks So.

WBA stock could be a high-conviction investment for 2023 as Walgreens ambitiously expands into primary healthcare.

Don’t Count on a Comeback for Arrival (ARVL) Stock

Arrival's headcount reduction plan is drastic and probably won't prevent a long-term decline in ARVL stock.

If You Invested $1,000 in MSFT Stock 3 Years Ago, Here’s What You’d Have Today!

MSFT stock's post-pandemic rebound is a textbook example of why investors should stay the course with great companies.

Floki Inu Price Predictions: Where Will the FLOKI Crypto Go in 2023?

A variety of Floki Inu price predictions might add clarity in the fast-moving world of dog-themed crypto coins.